Quick Answer
FRACTYL HEALTH, INC. reported R&D Expense of $74.54 million for fiscal year 2025.
FRACTYL HEALTH, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $74.54M | +5.8% |
| 2024 | $70.47M | +85.3% |
| 2023 | $38.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.46M | -8.1% | -17.5% |
| June 30, 2025 | $21.15M | +26.2% | +8.8% |
| March 31, 2025 | $19.43M | +34.7% | +2.3% |
| September 30, 2024 | $19.00M | +102.6% | +13.4% |
| June 30, 2024 | $16.76M | +83.4% | +16.2% |
| March 31, 2024 | $14.42M | +54.3% | +53.7% |
| September 30, 2023 | $9.38M | — | +2.6% |
| June 30, 2023 | $9.14M | — | -2.2% |
- FRACTYL HEALTH, INC. showed an increase of +5.8% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, FRACTYL HEALTH, INC.’s r&d expense has grown by 96.0% (from $38.04 million to $74.54 million).
- The most recent figure is from FRACTYL HEALTH, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: